HC Wainwright & Co. reiterates Buy rating on SpyGlass Pharma, $37 price target

HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.

Original reporting
Published Oct 5, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on SpyGlass Pharma, $37 price target — source image
Decision brief

The 30-second read

Med
01

Why it matters

Analyst upgrade could attract buying pressure, but trial outcomes remain uncertain.

02

Market read

Analyst rating change provides a fresh catalyst for the micro‑cap biotech.

03

What to watch

Funding needs for Phase 3 trial and regulatory risk

Relevance 7/10Novelty 6/10Timing: today

Background

Analyst reiterates Buy rating with $37 price target for SpyGlass Pharma.

Market effects

Potential uplift for glaucoma treatment sector

Limited to US biotech investors

Modest, confined to niche ophthalmology market

Counterpoint

Rating may be premature without trial data release

Key entities

  • SpyGlass Pharma

    Biotech firm developing intraocular drug delivery system.

Related articles

$SGPHighAI 8/10

Stifel raises SpyGlass Pharma stock price target to $44

Stifel raised its price target for SpyGlass Pharma (NASDAQ:SGP) to $44 from $42, maintaining a Buy rating. The stock has gained 40% in six months but declined 9.8% recently, trading at $33.32. The update follows a conference and Q3 earnings, with a higher probability of success for BIM-DRS. The company also reported positive trial data and acquired Advanced Vision Science for $13M.

$SGPMedAI 8/10

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates • Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatopro

$SGPMedAI 8/10

SpyGlass Pharma’s BIM-IOL Cuts IOP 37% at 4 Years, 86% Drop-Free

SpyGlass Pharma (SGP) reported 4-year trial data for its BIM-IOL System, showing a 37% mean reduction in intraocular pressure (IOP) and no adverse events. The trial involved 21 patients with glaucoma or ocular hypertension. The company plans to pursue a 505(b)(2) NDA with the FDA, with Phase 3 trials ongoing. The BIM-IOL System is designed to deliver bimatoprost for up to 7 years from a single implant during cataract surgery.